Chunxia Su

7.3k citations

181 papers · 4.5k indexed · h-index 36

Impact in

Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment

Papers in ⓘ

Oncology 125
- Cancer Immunotherapy and Biomarkers 60
- Lung Cancer Research Studies 55
- Colorectal Cancer Treatments and Studies 17
Pulmonary and Respiratory Medicine 105
- Lung Cancer Treatments and Mutations 96
- Lung Cancer Diagnosis and Treatment 15

Co-authors: Shengxiang Ren (85 shared papers)Xuefei Li (55 shared papers)Chao Zhao (49 shared papers)Tao Jiang (49 shared papers)Xiaoxia Chen (37 shared papers)Fei Zhou (40 shared papers)Guanghui Gao (36 shared papers)Caicun Zhou (27 shared papers)
Journals: Lung Cancer (18 papers)Journal of Thoracic Oncology (15 papers)Translational Lung Cancer Research (15 papers)Frontiers in Oncology (8 papers)International Journal of Cancer (6 papers)
Partner nations: China United States United Kingdom

In The Last Decade

Chunxia Su

167 papers receiving 4.4k citations

Peers

Countries citing papers authored by Chunxia Su

Since Specialization

Citations

This map shows the geographic impact of Chunxia Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chunxia Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chunxia Su more than expected).

Fields of papers citing papers by Chunxia Su

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chunxia Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chunxia Su. The network helps show where Chunxia Su may publish in the future.

Co-authors

The 25 scholars most cited alongside Chunxia Su, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Chunxia Su Line = papers co-authored together Chunxia Su links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 181 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer Cancer Immunology Research ·Sha Zhao, Shengxiang Ren, Tao Jiang, Bo Zhu, Xuefei Li, Chao Zhao, Yijun Jia, Jinpeng Shi, Limin Zhang, Xiaozhen Liu, Meng Qiao, Xiaoxia Chen, Chunxia Su, Hui Yu, Caicun Zhou, Jun Zhang, D. Ross Camidge, Fred R. Hirsch	2019	246
2	Continuous inertial cavitation evokes massive ROS for reinforcing sonodynamic therapy and immunogenic cell death against breast carcinoma Nano Today ·Yifei Yin, Xingwu Jiang, Liping Sun, Hongyan Li, Chunxia Su, Yan Zhang, Guang Xu, Xiaolong Li, Chong-Ke Zhao, Yu Chen, Hui‐Xiong Xu, Kun Zhang	2020	187
3	MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer Lung Cancer ·Bing Li, Shengxiang Ren, Xuefei Li, Yongsheng Wang, David Garfield, Songwen Zhou, Xiaoxia Chen, Chunxia Su, Mo Chen, Peng Kuang, Guanghui Gao, Yayi He, Lihong Fan, Fei Ke, Caicun Zhou, Gerald Schmit-Bindert	2013	157
4	EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: Implications for combination therapies International Journal of Cancer ·Yijun Jia, Xuefei Li, Tao Jiang, Sha Zhao, Chao Zhao, Limin Zhang, Xiaozhen Liu, Jinpeng Shi, Meng Qiao, Jiawei Luo, Sangtian Liu, Ruoshuang Han, Chunxia Su, Shengxiang Ren, Caicun Zhou	2019	126
5	Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer Lung Cancer ·Sha Zhao, Guanghui Gao, Wei Li, Xuefei Li, Chao Zhao, Tao Jiang, Yijun Jia, Yayi He, Aiwu Li, Chunxia Su, Shengxiang Ren, Xiaoxia Chen, Caicun Zhou	2019	121
6	Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is effective as first‐line treatment of advanced non‐small‐cell lung cancer with mutated EGFR: A meta‐analysis from six phase III randomized controlled trials International Journal of Cancer ·Guanghui Gao, Shengxiang Ren, Aiwu Li, Jianfang Xu, Qinghua Xu, Chunxia Su, Jian Guo, Qinfang Deng, Caicun Zhou	2011	113
7	Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn? Journal of Thoracic Oncology ·Meng Qiao, Tao Jiang, Xinyu Liu, Shiqi Mao, Fei Zhou, Xuefei Li, Chao Zhao, Xiaoxia Chen, Chunxia Su, Shengxiang Ren, Caicun Zhou	2021	113
8	EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases Journal of Thoracic Oncology ·Tao Jiang, Chunxia Su, Xuefei Li, Chao Zhao, Fei Zhou, Shengxiang Ren, Caicun Zhou, Jun Zhang	2016	110
9	Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers BMC Cancer ·Tao Jiang, Xiaofeng Xu, Meng Qiao, Xuefei Li, Chao Zhao, Fei Zhou, Guanghui Gao, Fengying Wu, Xiaoxia Chen, Chunxia Su, Shengxiang Ren, Changyun Zhai, Caicun Zhou	2018	94
10	Reactive oxygen species scavenging and inflammation mitigation enabled by biomimetic prussian blue analogues boycott atherosclerosis Journal of Nanobiotechnology ·Yan Zhang, Yifei Yin, Wei Zhang, Hongyan Li, Taixia Wang, Haohao Yin, Liping Sun, Chunxia Su, Kun Zhang, Hui‐Xiong Xu	2021	88
11	Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma Journal of Hematology & Oncology ·Tao Jiang, Jinpeng Shi, Zhengwei Dong, Likun Hou, Chao Zhao, Xuefei Li, Beibei Mao, Wei Zhu, Xianchao Guo, Henghui Zhang, Ji He, Xiaoxia Chen, Chunxia Su, Shengxiang Ren, Chunyan Wu, Caicun Zhou	2019	87
12	Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors Lung Cancer ·Xiangling Chu, Jing Zhao, Juan Zhou, Fei Zhou, Tao Jiang, Sen Jiang, Xiwen Sun, Xiaofang You, Fengying Wu, Shengxiang Ren, Caicun Zhou, Chunxia Su	2020	86
13	Pan-cancer analysis of ARID1A Alterations as Biomarkers for Immunotherapy Outcomes Journal of Cancer ·Tao Jiang, Xiaoxia Chen, Chunxia Su, Shengxiang Ren, Caicun Zhou	2019	83
14	Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors Lung Cancer ·Tao Jiang, Yuchen Bai, Fei Zhou, Wei Li, Guanghui Gao, Chunxia Su, Shengxiang Ren, Xiaoxia Chen, Caicun Zhou	2019	73
15	ROS1 fusions in Chinese patients with non-small-cell lung cancer Annals of Oncology ·W. Cai, X. Li, Chunxia Su, Lihong Fan, Li-Mou Zheng, K. Fei, C. Zhou, C. Manegold, Gerald Schmid‐Bindert	2013	69
16	Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma Oncotarget ·Qi Wang, Ningning Cheng, Xuefei Li, Hui Pan, Chunyu Li, Shengxiang Ren, Chunxia Su, Weijing Cai, Chao Zhao, Limin Zhang, Caicun Zhou	2016	69
17	Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis Cancer Immunology Immunotherapy ·Tao Jiang, Meng Qiao, Chao Zhao, Xuefei Li, Guanghui Gao, Chunxia Su, Shengxiang Ren, Caicun Zhou	2018	67
18	Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients Translational Oncology ·Xuefei Li, Ruixin Ren, Shengxiang Ren, Xiaoxia Chen, Weijing Cai, Fei Zhou, Yishi Zhang, Chunxia Su, Chao Zhao, Jiayu Li, Ningning Cheng, Mingchuan Zhao, Caicun Zhou	2014	64
19	Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancer Cancer ·Terry L. Ng, Yiwei Liu, Anastasios Dimou, Tejas Patil, Dara L. Aisner, Zhengwei Dong, Tao Jiang, Chunxia Su, Chunyan Wu, Shengxiang Ren, Caicun Zhou, D. Ross Camidge	2018	64
20	Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF Cancer Medicine ·Xibin Zhuang, Chao Zhao, Jiayu Li, Chunxia Su, Xiaoxia Chen, Shengxiang Ren, Xuefei Li, Caicun Zhou	2019	63

About Chunxia Su

Chunxia Su is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Immunology and Biotechnology, having authored 181 papers that have together received 4.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (96 papers), Cancer Immunotherapy and Biomarkers (60 papers), Lung Cancer Research Studies (55 papers), Cancer Genomics and Diagnostics (20 papers), Colorectal Cancer Treatments and Studies (17 papers), Lung Cancer Diagnosis and Treatment (15 papers), Immunotherapy and Immune Responses (10 papers) and RNA modifications and cancer (9 papers). The work is most often cited by research in Oncology (2.6k citations), Pulmonary and Respiratory Medicine (2.3k citations), Cancer Research (996 citations), Immunology (541 citations) and Molecular Biology (1.3k citations). Chunxia Su has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Shengxiang Ren, Xuefei Li, Chao Zhao, Tao Jiang, Xiaoxia Chen, Fei Zhou, Guanghui Gao, Caicun Zhou, Caicun Zhou and Caicun Zhou. Their work appears in journals such as Lung Cancer, Journal of Thoracic Oncology, Translational Lung Cancer Research, Frontiers in Oncology and International Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact